Webinar: Fast-Track Development of an In Vitro 3D Lung/Immune Cell Model Using the Quasi Vivo® System

Date: 25 June 2018 Location: Online event City: Online event Country: Online event

Current in vitro lung models often involve the use of Transwells® cell culture inserts for static cultures which lacks the biomechanical cues experienced in vivo that affects how cells behave.


More advanced lung models include microfluidic devices which provide miniaturisation and selected advantages. However, moving cells from a macroscopic culture environment of dishes, flasks and well-plates to microfluidic cell culture provides a potentially problematic obstacle requiring extensive revision of your existing culture protocols.


The Quasi Vivo® 600 is a milli-fluidic bioreactor designed to be fully compatible with standard 24 well plate Transwells® cell culture inserts, letting you easily transfer your standard static cell culture protocols into fluid flow and allowing cells to be cultured at an air liquid interface.  


Chandorkar et al. (2017)1 recently demonstrated that the QV600 system provides significant benefits in the development of airway cells. The perfusion of media provides cells with a constant supply of nutrients and removal of waste, resulting in NHBE cells showing:

  • Significantly accelerated and higher ciliogenesis
  • Increased cilia movement
  • Enhanced mucus production
  • Improved barrier function    



  Watch the webinar on our Bioscience website


This improved functionality under perfusion can reduce the time taken for experimental procedures by up to two thirds.


Join Dr. Shehnaz Ahmed (Technical Support Executive at Kirkstall Ltd) and special guest presenter Dr. Doris Wilflingseder (Associate Professor at Innsbruck Medical University and Vice Director at Division of Hygiene and Medical Microbiology) as they discuss how to develop a physiologically relevant in vitro lung model for disease modelling and drug development applications.    




Date and Time:  

Monday, 25 June 2018

8 AM PDT (Los Angeles) / 10 AM CDT (Chicago) / 4 PM BST (London) / 5 PM CEST (Berlin)




 Dr. Doris Wilflingseder, Assoc. Professor at Medical University of Innsbruck  Dr Bhumika Singh, Chief Scientific Officer, Kirkstall Ltd

Dr. Doris Wilflingseder

Assoc. Professor

Medical University of Innsbruck

View biography

Dr. Doris Wilflingseder studied zoology at the Leopold-Franzens-University in Innsbruck, Austria. During her thesis at the Division of Physiology, Medical University Innsbruck, and her first postdoc years at the Division of Hygiene and Medical Microbiology, Medical University Innsbruck, she focused on cell biology and immunology and worked on signal mechanisms – i.e. MAPK signaling – in human primary cell models upon stimulation with fungal or viral pathogens.

Dr. Wilflingseder continued these analyses using dendritic cells (DC) and differentially opsonized HIV-1 during her stay in collaboration with Paul Kellam at the Division of Infection and Immunity, University College London.

Her research group at the Division of Hygiene and Medical Microbiology of the Medical University Innsbruck is interested in modulation of DC and macrophage function by the opsonisation pattern of pathogens, i.e. HIV-1, HIV-2 or Aspergillus fumigatus in relevant 3-dimensional cell culture microenvironments. To address these issues they used molecular biologic, high content/high throughput imaging and immunologic approaches and primary cell models – where possible – or appropriate cell lines for e.g. gene editing approaches.

Dr. Bhumika Singh

Chief Scientific Officer

Kirkstall Ltd

View biography

Dr. Bhumika Singh (Chief Scientific Officer at Kirkstall Ltd.) completed her PhD in Neuroscience at University Medicine Charite in Berlin, Germany before moving on to postdoctoral research at Miltenyi Biotec, Cologne to concentrate on developing in-vitro models for neuronal injury.

In moving to the UK, Dr Singh worked at Unilever for over ten years as a Cell Culture/Tissue Engineer and as Lead Scalp Skin Scientist. During this time she led technical projects for discovery of novel therapeutic routes and developed advanced in-vitro models for skin health at Unilever.

Dr. Singh’s key interest is to further develop the science for the Quasi Vivo® technology for efficient drug discovery and animal free research.


  Watch the webinar on our Bioscience website           






Learn more about the QuasiVivo® System.




1 Chandokar, P. et al. Fast-track development of an in vitro 3D lung/immune cell model to study Aspergillus infections. Scientific Reports. volume 7, Article number: 11644 (2017)